Skip to main content
Log in

Rapid detection of common CARD15 variants in patients with inflammatory bowel disease

  • Original Research Article
  • Published:
Molecular Diagnosis Aims and scope Submit manuscript

Abstract

Background: Three mutations (R702W, G908R, and 1007fs) within the CARD15 gene have been identified as independent risk factors for the development of Crohn’s disease (CD). Virtually all studies investigating the occurrence of these mutations in patients with CD have used separate PCR-based methods to screen patient DNA, here we describe a novel multiplex amplification refractory mutation system (ARMS) assay that allows the simultaneous detection of R702W, G908R, and 1007fs, and a fourth CARD15 variant, P268S, at a fraction of the cost of the pre-existing genotyping assays.

Methods: Allele-specific primer sets were designed for each CARD15 variant, optimized separately for annealing temperature and MgCl2 and then multiplexed. The mutant- and wild-type-specific primers were split across two tubes so that each multiplex reaction was internally controlled for amplification failure. An additional primer pair specific to β2-microglobulin was included as an independent control for DNA quality. The specificity of each primer set was tested using positive controls that had been validated by sequencing, and the robustness of the final ARMS assay was assessed by genotyping 111 Caucasian patients with inflammatory bowel disease (IBD).

Results: The specificity of each primer set was confirmed using a sequence validated positive control for each of the four CARD15 variants. Of the 111 DNA samples screened with our ARMS assay, a clear CARD15 genotype was obtained for 109 patients.

Discussion and conclusions: Given the potential predictive value of R702W, G980R, and 1007fs, a robust genotyping method for these variants would be of considerable value both in diagnostic and research settings. Our ARMS assay only takes 3–4 hours to perform once DNA has been extracted and requires only 1U of Taq DNA polymerase, making it a rapid, reliable, and cost-effective alternative to current CARD15 genotyping methods.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I

Similar content being viewed by others

References

  1. Podolsky DK. The current future understanding of inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2002; 16(6): 933–43

    Article  PubMed  Google Scholar 

  2. Rubin DT, Hanauer SB. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12(8): 855–62

    Article  PubMed  CAS  Google Scholar 

  3. Somerville KW, Logan RF, Edmond M, et al. Smoking and Crohn’s disease. BMJ (Clin Res Ed) 1984; 289(6450): 954–6

    Article  CAS  Google Scholar 

  4. Corrao G, Tragnone A, Caprilli R, et al. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC). Int J Epidemiol 1998; 27(3): 397–404

    CAS  Google Scholar 

  5. Card T, Logan RF, Rodrigues LC, et al. Antibiotic use and the development of Crohn’s disease. Gut 2004; 53(2): 246–50

    Article  PubMed  CAS  Google Scholar 

  6. Ekbom A, Montgomery SM. Environmental risk factors (excluding tobacco and microorganisms): critical analysis of old and new hypotheses. Best Pract Res Clin Gastroenterol 2004; 18(3): 497–508

    Article  PubMed  Google Scholar 

  7. Feeney MA, Murphy F, Clegg AJ, et al. A case-control study of childhood environmental risk factors for the development of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002; 14(5): 529–34

    Article  PubMed  Google Scholar 

  8. el-Omar E, Penman I, Cruikshank G, et al. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. Gut 1994; 35(10): 1385–8

    Article  PubMed  CAS  Google Scholar 

  9. Parente F, Molteni P, Bollani S, et al. Prevalence of Helicobacter pylori infection and related upper gastrointestinal lesions in patients with inflammatory bowel diseases: across-sectional study with matching. Scand J Gastroenterol 1997; 32(11): 1140–6

    Article  PubMed  CAS  Google Scholar 

  10. Orholm M, Binder V, Sorensen TI, et al. Concordance of inflammatory bowel disease among Danish twins: results of a nationwide study. Scand J Gastroenterol 2000; 35(10): 1075–81

    Article  PubMed  CAS  Google Scholar 

  11. Thompson NP, Driscoll R, Pounder RE, et al. Genetics versus environment in inflammatory bowel disease: results of a British twin study. BMJ 1996; 312(7023): 95–6

    Article  PubMed  CAS  Google Scholar 

  12. Tysk C, Lindberg E, Jarnerot G, et al. Ulcerative colitis and Crohn’s disease in an unselected population of monozygotic and dizygotic twins: a study of heritability and the influence of smoking. Gut 1988; 29(7): 990–6

    Article  PubMed  CAS  Google Scholar 

  13. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001; 411(6837): 603–6

    Article  PubMed  CAS  Google Scholar 

  14. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001; 411(6837): 599–603

    Article  PubMed  CAS  Google Scholar 

  15. Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001; 276(7): 4812–8

    Article  PubMed  CAS  Google Scholar 

  16. Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003; 3(5): 371–82

    Article  PubMed  CAS  Google Scholar 

  17. Girardin SE, Boneca IG, Viala J, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278(11): 8869–72

    Article  PubMed  CAS  Google Scholar 

  18. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002; 70(4): 845–57

    Article  PubMed  CAS  Google Scholar 

  19. Yang SK, Loftus EV, Sandborn WJ. Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel Dis 2001; 7(3): 260–70

    Article  PubMed  CAS  Google Scholar 

  20. Sonnenberg A, Wasserman IH. Epidemiology of inflammatory bowel disease among US military veterans. Gastroenterology 1991; 101(1): 122–30

    PubMed  CAS  Google Scholar 

  21. Inoue N, Tamura K, Kinouchi Y, et al. Lack of common NOD2 variants in Japanese patients with Crohn’s disease. Gastroenterology 2002; 123(1): 86–91

    Article  PubMed  CAS  Google Scholar 

  22. Cavanaugh JA, Adams KE, Quak EJ, et al. CARD15/NOD2 risk alleles in the development of Crohn’s disease in the Australian population. Ann Hum Genet 2003; 67 (Pt 1): 35–41

    Article  PubMed  CAS  Google Scholar 

  23. Brant SR, Picco MF, Achkar JP, et al. Defining complex contributions of NOD2/ CARD15 gene mutations, age at onset, and tobacco use on Crohn’s disease phenotypes. Inflamm Bowel Dis 2003; 9(5): 281–9

    Article  PubMed  Google Scholar 

  24. Buning C, Genschel J, Buhner S, et al. Mutations in the NOD2/CARD15 gene in Crohn’s disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther 2004; 19(10): 1073–8

    Article  PubMed  CAS  Google Scholar 

  25. Guo QS, Xia B, Jiang Y, et al. NOD2 3020insC frameshift mutation is not associated with inflammatory bowel disease in Chinese patients of Han nationality. World J Gastroenterol 2004; 10(7): 1069–71

    PubMed  CAS  Google Scholar 

  26. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet 2001; 357(9272): 1925–8

    Article  PubMed  CAS  Google Scholar 

  27. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn’s disease: a cohort study. Lancet 2002; 359(9318): 1661–5

    Article  PubMed  CAS  Google Scholar 

  28. Helio T, Halme L, Lappalainen M, et al. CARD15/NOD2 gene variants are associated with familiarly occurring and complicated forms of Crohn’s disease. Gut 2003; 52(4): 558–62

    Article  PubMed  CAS  Google Scholar 

  29. Linde K, Boor PP, Houwing-Duistermaat JJ, et al. Card15 and Crohn’s disease: healthy homozygous carriers of the 3020insC frameshift mutation. Am J Gastroenterol 2003; 98(3): 613–7

    Article  PubMed  Google Scholar 

  30. Vermeire S, Wild G, Kocher K, et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 2002; 71(1): 74–83

    Article  PubMed  CAS  Google Scholar 

  31. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18(4): 395–400

    Article  PubMed  CAS  Google Scholar 

  32. Ciulla TA, Sklar RM, Hauser SL. A simple method for DNA purification from peripheral blood. Anal Biochem 1988; 174(2): 485–8

    Article  PubMed  CAS  Google Scholar 

  33. Sugimura K, Taylor KD, Lin YC, et al. A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews. Am J Hum Genet 2003; 72(3): 509–18

    Article  PubMed  CAS  Google Scholar 

  34. Palmieri O, Toth S, Ferraris A, et al. CARD15 genotyping in inflammatory bowel disease patients by multiplex pyrosequencing. Clin Chem 2003; 49(10): 1675–9

    Article  PubMed  CAS  Google Scholar 

  35. Vermeire S. NOD2/CARD15: relevance in clinical practice. Best Pract Res Clin Gastroenterol 2004; 18(3): 569–75

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We wish to thank Professor Kimmo Kontula at the Helsinki University Central Hospital, Finland, for providing positive controls for R702W, G908R, and 1007fs.

Dr Roberts is the recipient of Health Sciences Career Development Programme Award from the University of Otago, and Dr Gearry is a Canterbury Medical Research Foundation Fellow. This work was funded by the Canterbury Medical Research Foundation, Lottery Grants Health Board (New Zealand), and the Health Research Council of New Zealand. None of the authors have any conflicts of interest directly relevant to this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rebecca L. Roberts.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roberts, R.L., Gearry, R.B., Barclay, M.L. et al. Rapid detection of common CARD15 variants in patients with inflammatory bowel disease. CNS Drugs 8, 101–105 (2004). https://doi.org/10.1007/BF03260052

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03260052

Keywords

Navigation